Learning Objectives After completing this course, the reader will be able to: Discuss the
physiology of the different clinical hypersensitivity and infusion reactions to monoclonal …

Monoclonal antibodies—including rituximab, alemtuzumab, trastuzumab, bevacizumab,
cetuximab, and panitumumab—have improved the treatment of various malignancies …

Cancer Nursing: Principles and Practice, Eighth Edition continues as the gold standard in
oncology nursing. With contributions from the foremost experts in the field, it has remained …

Platinum‐containing chemotherapy agents (cisplatin, carboplatin, oxaliplatin) have been
approved in the first‐line setting of numerous malignancies, such as ovarian, bladder, head …

OBJECTIVES: To review clinical hypersensitivity reactions related to common cancer
chemotherapy agents and to discuss potential management strategies. DATA SOURCES …

Background Desensitization to antineoplastic agents is becoming a standard of care. Efforts
to establish and improve these techniques are being made at many institutions. Our aims …

Hypersensitivity reactions (HSRs) to chemotherapy may prevent patients from receiving the
most effective therapy. This review was undertaken to identify evidence-based preventive …

Oxaliplatin is a platinum salt that is particularly effective in treating gastrointestinal tumours.
Its increased use has resulted in emergence of allergic reactions, including anaphylactic …

Hypersensitivity reactions (HSRs) to platinum drugs are increasing due to their extensive
use in a wide variety of malignancies and the repeated exposures in patients with increased …

Background Hypersensitivity reactions to antineoplastic agents may lead to discontinuation
of first-line treatments. Rapid drug desensitization (RDD) allows for a safe reintroduction in …